Innovative technology to detect abnormal heart rhythms recommended by NICE for NHS use while further data is collected
Zio ZT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use with the caveat that further data must be collected.
-
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK
-
.png?v=637418096396395701)
NICE is getting ready for the end of the transition period after Brexit
NICE has a key role in evaluation and access to new and innovative products for the health system, playing an important role in ensuring the UK remains a destination of choice for the life sciences sector.
-
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
